The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
The recent introduction of the 5,000L single-use bioreactor (SUB) is helping to revolutionize biologics manufacturing by bridging the gap between small and large-scale production. This new technology choice offers biotech and pharma companies, as well as their CDMO partners, greater flexibility to respond to fluctuating demands quickly and efficiently. As the market for complex biologics grows, capacity planning becomes increasingly critical—and even more challenging.
This whitepaper outlines how to evaluate capacity needs and the benefits of using SUBs at different drug development stages. Key topics include the benefits of 5,000L SUBs, improvements in turndown ratios and oxygen transfer rates, and the efficiency and sustainability advantages they offer over stainless-steel bioreactors. Additionally, it highlights what to consider when selecting a CDMO partner for manufacturing with SUBs to ensure reliability, flexibility, and collaboration.
